GlassScriptPhysician profile
Boutros El-Haddad
NPI 1710103080
$4,099.06
in general payments reported to CMS, 2019-2025
21 companies · $1,245 in 2025
The $1,245 reported for 2025 was more than what 83% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $302 · 2022: $402 · 2023: $656 · 2024: $1,495 · 2025: $1,245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,496 · Travel and Lodging: $886 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,495.87 |
| Travel and Lodging | $886.00 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $921.75 | 2024 | |
| Amgen INC. | $513.59 | 2021-2025 | Tavneos |
| Fresenius USA Marketing, INC. | $508.92 | 2021-2025 | Velphoro, Velphoro, Korsuva |
| Travere Therapeutics, INC. | $367.01 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $316.92 | 2022-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $291.47 | 2021-2025 | Jynarque, Voyxact |
| Bayer Healthcare Pharmaceuticals INC. | $205.35 | 2022-2025 | |
| Nxstage Medical, INC. | $176.00 | 2023-2025 | Liberty Select Cycler, Nxstage System One |
| Calliditas Therapeutics US INC. | $146.80 | 2022-2025 | Tarpeyo |
| Alexion Pharmaceuticals, INC. | $119.75 | 2021-2024 | Ultomiris |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $98.01 | 2021 | |
| Vifor Pharma, INC. | $84.40 | 2021-2025 | Veltassa, Korsuva |
| Novartis Pharmaceuticals Corporation | $74.23 | 2024-2025 | |
| Glaxosmithkline, LLC. | $68.90 | 2023 | Benlysta |
| Horizon Therapeutics Plc | $53.25 | 2022-2023 | Procysbi, Krystexxa |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.62 | 2022-2025 | Jardiance |
| Opko Pharmaceuticals, LLC | $31.19 | 2021-2022 | |
| Apellis Pharmaceuticals, INC. | $28.94 | 2025 | Empaveli |
| Mallinckrodt Hospital Products INC. | $21.69 | 2024 | Terlivaz |
| Ardelyx, INC. | $18.27 | 2025 | Ibsrela |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Boutros El-Haddad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.